Reduced growth hormone response to L-dopa and pyridostigmine in obesity

Eunjig Lee, K. R. Kim, K. M. Lee, Sungkil Lim, H. C. Lee, J. H. Lee, D. J. Lee, K. B. Huh

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The purpose of this study was to evaluate growth hormone (GH) secretion and clarify the factors influencing GH secretion in obesity. Nine obese subjects and eight controls were recruited. We compared the GH response to L-dopa with or without pyridostigmine pretreatment in obese and control subjects. Plasma glucose, insulin, insulin-like growth factor I (IGF-I) and free fatty acid (FFA) were also measured. Growth hormone responses and GH area under the response curve (AUC) to L-dopa were significantly lower in obese subjects than those in controls. Pyridostigmine significantly enhanced the GH response to L-dopa in both obese and control subjects. However, enhanced GH responses in obese subjects were attenuated biologically and lower than those in controls with L-dopa only. Plasma levels of insulin and FFA were significantly higher in obese subjects than those in controls. Body mass index had a positive correlation with the levels of insulin and FFA. However, GH AUC had an inverse correlation with insulin and FFA in obese subjects and controls. Stepwise multiple regression analysis showed a highly significant effect of FFA on GH AUC, but no independent influence of other factors on GH AUC. The reduced GH secretion found in this study suggests an increase in somatostatinergic tone and a diminished release of GHRH from the hypothalamus in obesity. However, other factors including hyperinsulinemia and increased plasma FFA may play an important additional role in the secretory dysfunction of GH in obesity.

Original languageEnglish
Pages (from-to)465-468
Number of pages4
JournalInternational Journal of Obesity
Volume18
Issue number7
Publication statusPublished - 1994 Jan 1

Fingerprint

Pyridostigmine Bromide
Levodopa
Growth Hormone
Obesity
Nonesterified Fatty Acids
Area Under Curve
Insulin
Hyperinsulinism
Insulin-Like Growth Factor I
Hypothalamus

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics

Cite this

Lee, E., Kim, K. R., Lee, K. M., Lim, S., Lee, H. C., Lee, J. H., ... Huh, K. B. (1994). Reduced growth hormone response to L-dopa and pyridostigmine in obesity. International Journal of Obesity, 18(7), 465-468.
Lee, Eunjig ; Kim, K. R. ; Lee, K. M. ; Lim, Sungkil ; Lee, H. C. ; Lee, J. H. ; Lee, D. J. ; Huh, K. B. / Reduced growth hormone response to L-dopa and pyridostigmine in obesity. In: International Journal of Obesity. 1994 ; Vol. 18, No. 7. pp. 465-468.
@article{3a5f04ed04414259ab5c5e592dceae18,
title = "Reduced growth hormone response to L-dopa and pyridostigmine in obesity",
abstract = "The purpose of this study was to evaluate growth hormone (GH) secretion and clarify the factors influencing GH secretion in obesity. Nine obese subjects and eight controls were recruited. We compared the GH response to L-dopa with or without pyridostigmine pretreatment in obese and control subjects. Plasma glucose, insulin, insulin-like growth factor I (IGF-I) and free fatty acid (FFA) were also measured. Growth hormone responses and GH area under the response curve (AUC) to L-dopa were significantly lower in obese subjects than those in controls. Pyridostigmine significantly enhanced the GH response to L-dopa in both obese and control subjects. However, enhanced GH responses in obese subjects were attenuated biologically and lower than those in controls with L-dopa only. Plasma levels of insulin and FFA were significantly higher in obese subjects than those in controls. Body mass index had a positive correlation with the levels of insulin and FFA. However, GH AUC had an inverse correlation with insulin and FFA in obese subjects and controls. Stepwise multiple regression analysis showed a highly significant effect of FFA on GH AUC, but no independent influence of other factors on GH AUC. The reduced GH secretion found in this study suggests an increase in somatostatinergic tone and a diminished release of GHRH from the hypothalamus in obesity. However, other factors including hyperinsulinemia and increased plasma FFA may play an important additional role in the secretory dysfunction of GH in obesity.",
author = "Eunjig Lee and Kim, {K. R.} and Lee, {K. M.} and Sungkil Lim and Lee, {H. C.} and Lee, {J. H.} and Lee, {D. J.} and Huh, {K. B.}",
year = "1994",
month = "1",
day = "1",
language = "English",
volume = "18",
pages = "465--468",
journal = "International Journal of Obesity",
issn = "0307-0565",
publisher = "Nature Publishing Group",
number = "7",

}

Lee, E, Kim, KR, Lee, KM, Lim, S, Lee, HC, Lee, JH, Lee, DJ & Huh, KB 1994, 'Reduced growth hormone response to L-dopa and pyridostigmine in obesity', International Journal of Obesity, vol. 18, no. 7, pp. 465-468.

Reduced growth hormone response to L-dopa and pyridostigmine in obesity. / Lee, Eunjig; Kim, K. R.; Lee, K. M.; Lim, Sungkil; Lee, H. C.; Lee, J. H.; Lee, D. J.; Huh, K. B.

In: International Journal of Obesity, Vol. 18, No. 7, 01.01.1994, p. 465-468.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Reduced growth hormone response to L-dopa and pyridostigmine in obesity

AU - Lee, Eunjig

AU - Kim, K. R.

AU - Lee, K. M.

AU - Lim, Sungkil

AU - Lee, H. C.

AU - Lee, J. H.

AU - Lee, D. J.

AU - Huh, K. B.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - The purpose of this study was to evaluate growth hormone (GH) secretion and clarify the factors influencing GH secretion in obesity. Nine obese subjects and eight controls were recruited. We compared the GH response to L-dopa with or without pyridostigmine pretreatment in obese and control subjects. Plasma glucose, insulin, insulin-like growth factor I (IGF-I) and free fatty acid (FFA) were also measured. Growth hormone responses and GH area under the response curve (AUC) to L-dopa were significantly lower in obese subjects than those in controls. Pyridostigmine significantly enhanced the GH response to L-dopa in both obese and control subjects. However, enhanced GH responses in obese subjects were attenuated biologically and lower than those in controls with L-dopa only. Plasma levels of insulin and FFA were significantly higher in obese subjects than those in controls. Body mass index had a positive correlation with the levels of insulin and FFA. However, GH AUC had an inverse correlation with insulin and FFA in obese subjects and controls. Stepwise multiple regression analysis showed a highly significant effect of FFA on GH AUC, but no independent influence of other factors on GH AUC. The reduced GH secretion found in this study suggests an increase in somatostatinergic tone and a diminished release of GHRH from the hypothalamus in obesity. However, other factors including hyperinsulinemia and increased plasma FFA may play an important additional role in the secretory dysfunction of GH in obesity.

AB - The purpose of this study was to evaluate growth hormone (GH) secretion and clarify the factors influencing GH secretion in obesity. Nine obese subjects and eight controls were recruited. We compared the GH response to L-dopa with or without pyridostigmine pretreatment in obese and control subjects. Plasma glucose, insulin, insulin-like growth factor I (IGF-I) and free fatty acid (FFA) were also measured. Growth hormone responses and GH area under the response curve (AUC) to L-dopa were significantly lower in obese subjects than those in controls. Pyridostigmine significantly enhanced the GH response to L-dopa in both obese and control subjects. However, enhanced GH responses in obese subjects were attenuated biologically and lower than those in controls with L-dopa only. Plasma levels of insulin and FFA were significantly higher in obese subjects than those in controls. Body mass index had a positive correlation with the levels of insulin and FFA. However, GH AUC had an inverse correlation with insulin and FFA in obese subjects and controls. Stepwise multiple regression analysis showed a highly significant effect of FFA on GH AUC, but no independent influence of other factors on GH AUC. The reduced GH secretion found in this study suggests an increase in somatostatinergic tone and a diminished release of GHRH from the hypothalamus in obesity. However, other factors including hyperinsulinemia and increased plasma FFA may play an important additional role in the secretory dysfunction of GH in obesity.

UR - http://www.scopus.com/inward/record.url?scp=0028283710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028283710&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 465

EP - 468

JO - International Journal of Obesity

JF - International Journal of Obesity

SN - 0307-0565

IS - 7

ER -